WASHINGTON, D.C. -- FreedomWorks is pleased to announce the launch of the American Freedom Initiative (AFI), which aims to recommend deserving individuals to the Trump administration for pardons and commutations.

WASHINGTON, D.C. -- This past weekend in light of International Women's Day, FreedomWorks launched its seven-figure Women Win 2020 campaign which aims to increase turnout of suburban women in favor of free-market, conservative candidates this November. FreedomWorks’ grassroots community will utilize a dynamic and comprehensive approach to driving turnout through grassroots events, peer-to-peer texting and digital ads on social media.

WASHINGTON, D.C. -- In response to the decision to name Rep. Mark Meadows (R-N.C.) as White House Chief of Staff, Adam Brandon, FreedomWorks President, commented:

WASHINGTON, D.C. -- In response to the insertion of a provision calling for price controls on vaccines in the congressional coronavirus package, Adam Brandon, FreedomWorks’ President, commented:

WASHINGTON, D.C. -- In response to former Mayor of New York City, Mike Bloomberg’s (D-N.Y.) announcement today that he will suspend his 2020 Presidential Campaign, Adam Brandon, FreedomWorks President, commented:

WASHINGTON, D.C. -- In response to efforts by Democratic House leadership to tie the reauthorization of the USA PATRIOT Act to the coronavirus spending package, Jason Pye, FreedomWorks’ Vice President of Legislative Affairs, commented:

WASHINGTON, D.C. -- In response to Rep. Jerry Nadler (D-N.Y.), Chairman of the House Judiciary Committee’s, decision to cancel its hearing today on FISA reform at the behest of Rep. Adam Schiff (D-Calif.), Chairman of the House Intelligence Committee, Jason Pye, FreedomWorks’ Vice President of Legislative Affairs, commented:

WASHINGTON, D.C. -- In anticipation of the 2020 South Carolina Democratic Debate, Adam Brandon, FreedomWorks President, commented:

WASHINGTON, D.C. -- In response to Sen. Chuck Grassley’s (R-Iowa) most recent support for government mandated price controls on prescription drugs, Dan Savickas, FreedomWorks Regulatory Policy Manager, commented: